Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Provectus Biopharmaceuticals, Inc. (PVCT) had Return on Tangible Equity of 31.53% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$0.06M |
|
$-1.81M |
|
-- |
|
$0.06M |
|
$1.86M |
|
$-1.80M |
|
$-0.05M |
|
$-1.85M |
|
$-1.85M |
|
$-1.85M |
|
$-1.85M |
|
$-1.85M |
|
$-1.85M |
|
$-1.80M |
|
$-1.80M |
|
420.28M |
|
420.28M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$0.57M |
|
$0.00M |
|
$0.15M |
|
$0.72M |
|
$6.49M |
|
-- |
|
$0.10M |
|
$6.60M |
|
$-5.89M |
|
$-5.87M |
|
$-5.87M |
|
420.28M |
|
| Cash Flow Statement Financials | |
$-1.62M |
|
-- |
|
$1.54M |
|
$0.49M |
|
$0.42M |
|
$-0.07M |
|
$0.64M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.09 |
|
-- |
|
-- |
|
-- |
|
-0.40 |
|
100.00% |
|
-3132.79% |
|
-3132.79% |
|
-- |
|
-3222.13% |
|
-3156.61% |
|
$-1.62M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
-- |
|
-- |
|
-- |
|
31.45% |
|
|
Return on Tangible Equity |
31.53% |
-256.38% |
|
31.53% |
|
$-0.01 |
|
$-0.00 |
|
$-0.00 |
|